{"entity":{"id":"myd88","kind":"target","name":"MYD88","aka":["MYD88 innate immune signal transduction adaptor","Myeloid differentiation primary response protein MyD88"],"tldr":"MYD88 (Myeloid differentiation primary response protein MyD88) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 4 more.","summary":"Adapter protein involved in the Toll-like receptor and IL-1 receptor signalling pathway in the innate immune response. Acts via IRAK1, IRAK2, IRF7 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Increases IL-8 transcription.\n\nCIViC holds 5 clinical evidence items and 0 assertions across 2 variants, naming Paclitaxel, Ibrutinib, IRAK-1/4 Inhibitor and IMG-2005-5. Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.98, genetic association 0.00, somatic mutation 0.95). IntOGen calls it a driver in 10 cohorts (10 activating, 0 loss-of-function), covering Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:7562","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7562"},{"label":"UniProt Q99836","url":"https://www.uniprot.org/uniprotkb/Q99836/entry"},{"label":"NCBI Gene 4615","url":"https://www.ncbi.nlm.nih.gov/gene/4615"},{"label":"Ensembl ENSG00000172936","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172936"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets","intogen"],"cancers":["non-hodgkin-lymphoma","leukaemia","breast-cancer","dlbcl","all-leukemia","cll","waldenstrom"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["bcr-signalling"],"terms":[],"trials":["nct04274738"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 4 therapies; IntOGen calls it an activating (Act) driver in 10 cohorts; CIViC holds 5 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate.","Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Lymphoplasmacytic Lymphoma."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"MYD88","role":["drug-target","oncogene-driver","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:7562","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7562","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q99836","url":"https://www.uniprot.org/uniprotkb/Q99836/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene MYD88","url":"https://civicdb.org/features/3742","note":"5 evidence items, 0 assertions, 2 variants; diseases: Lymphoplasmacytic Lymphoma, Breast Cancer, Diffuse Large B-cell Lymphoma, Chronic Lymphocytic Leukaemia (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000172936","url":"https://platform.opentargets.org/target/ENSG00000172936/associations","note":"association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.70, diffuse large B-cell lymphoma 0.72, B-cell chronic lymphocytic leukaemia 0.70, non-Hodgkin lymphoma 0.83, Waldenstrom macroglobulinemia 0.50, breast cancer 0.54 (GraphQL API, CC0)"},{"label":"IntOGen MYD88","url":"https://www.intogen.org/search?gene=MYD88","note":"driver in 10 cohorts (Act 10, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"hgnc":"HGNC:7562","ensembl":"ENSG00000172936","uniprot":"Q99836","entrez":"4615","biology":"Adapter protein involved in the Toll-like receptor and IL-1 receptor signalling pathway in the innate immune response. Acts via IRAK1, IRAK2, IRF7 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Increases IL-8 transcription. Involved in IL-18-mediated signalling pathway. Activates IRF1 resulting in its rapid migration into the nucleus to mediate an efficient induction of IFN-beta, NOS2/INOS, and IL12A genes. Upon TLR8 activation by GU-rich single-stranded RNA (GU-rich RNA) derived from viruses such as SARS-CoV-2, SARS-CoV and HIV-1, induces IL1B release through NLRP3 inflammasome activation. Location: Cytoplasm; Nucleus (UniProt). Locus 3p22.2 (HGNC).","whereFound":["Non-Hodgkin lymphoma: Open Targets association 0.83 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL)","Leukaemia: Open Targets association 0.74 with leukaemia (MONDO_0005059)","Breast cancer: Open Targets association 0.54 with breast cancer (MONDO_0007254); CIViC evidence names this disease","Diffuse large B-cell lymphoma: Open Targets association 0.72 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease","Acute lymphoblastic leukaemia: Open Targets association 0.70 with acute lymphoblastic leukaemia (MONDO_0004967)","Chronic lymphocytic leukaemia: Open Targets association 0.70 with B-cell chronic lymphocytic leukaemia (MONDO_0004948); CIViC evidence names this disease"],"targetClass":"oncogene","prevalence":[]},"route":"/targets/myd88/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/"}],"pathway":[{"id":"bcr-signalling","kind":"pathway","name":"B-cell receptor / BTK signalling (to NF-κB)","route":"/pathways/bcr-signalling/"}],"trial":[{"id":"nct04274738","kind":"trial","name":"A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4","route":"/trials/nct04274738/"}]}}